Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 280-285

  Perlis, R H ^a   Fijal, B ^b   Dharia, S ^c   Houston, J P ^b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c PharmaNet/i3   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; CRF receptor type 1; duloxetine; single nucleotide polymorphisms

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE 3 RECEPTOR; DULOXETINE; PHOSPHODIESTERASE I; PLACEBO;

ADULT; ARTICLE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 GENE; DOPAMINE 3 RECEPTOR GENE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEAR RECEPTOR SUBFAMILY GROUP C MEMBER 1 GENE; PHARMACOGENETICS; PHOSPHODIESTERASE 1A GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; ANXIETY DISORDERS; BIOMARKERS, PHARMACOLOGICAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; THIOPHENES;

EID: 84878220008     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.62     Document Type: Article

References (22)

1. Levine J, Cole DP, Chengappa KN, Gershon S. Anxiety disorders and major depression, together or apart. Depress Anxiety 2001; 14: 94-104.
2. Schosser A, Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 2009; 24: 277-288.
3. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009; 65: 785-791.
4. Papiol S, Arias B, Gastó C, Gutiórrez B, Catalán R, Fañanás L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007; 104: 83-90.
5. Lenze EJ, Mantella RC, Shi P, Goate AM, Nowotny P, Butters MA et al. Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry 2011; 19: 482-490.
6. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225-233.
7. Perroud N, Bondolfi G, Uher R, Gex-Fabry M, Aubry JM, Bertschy G et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12: 365-377.
8. Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J Affect Disord 2011; 128: 56-63.
9. Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. J Clin Psychopharmacol 2010; 30: 672-677.
10. Gorwood P. Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy? Eur Psychiatry 2004; 19: 27-33.
11. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsy-chopharmacol 2008; 18: 673-681.
12. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychophar-macol 2007; 22: 167-174.
13. Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafax-ine extended-release and placebo-controlled trial. Psychol Med 2009; 39: 267-276.
14. Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007; 68: 1921-1930.
15. Jurinke C, van den Boom D, Cantor CR, Köster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2002; 187: 179-192.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
17. Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety 2009; 26: 984-992.
18. Thode K, Beuten J, Maher BS, Birmaher B, Ryan ND, Williamson DE. Hypothalamic-Pituitary-Adrenal axis activation in response to stress is moderated by polymorphic variants within the corticotropin-releasing hormone receptor 1. Biol Psychiatry 2008; 63(Suppl 7): 85S (abstract 255).
19. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 2009; 66: 681-685.
20. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007; 414: 155-158.
21. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004; 9: 1075-1082.
22. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010; 27: 417-425.